Repligen Corp. 10-Q Summary: Quarter Ended September 30, 1997
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 1997, and the six-month period ended on that date. Repligen Corporation has redirected its focus from clinical development of biological products to developing enabling technologies for drug discovery, including chemical compound library synthesis and screening assays. The Company also manufactures and markets products for monoclonal antibody production based on recombinant Protein A.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1997 | Six Months Ended Sep 30, 1997 |
|---|---|---|
| Total Revenues | $503,328 | $1,178,835 |
| Net Loss | $(241,801) | $(385,392) |
| Net Loss Per Share | $(0.02) | $(0.02) |
| Cash and Cash Equivalents (End of Period) | $3,080,267 | $3,080,267 |
| Working Capital | $3,693,750 | $3,693,750 |
| Total Current Liabilities | $350,960 | $350,960 |
| Accumulated Deficit | $(123,908,989) | $(123,908,989) |
Revenue Breakdown (Six Months): Research and development ($424,369), Product ($539,385), Investment income ($115,106), and Other ($99,975).
Expense Breakdown (Six Months): Research and development ($714,201), Selling, general and administrative ($622,208), and Cost of goods sold ($227,818).
Material Changes Versus Prior Period
- Revenue Decline: Total revenues decreased approximately 49% for the three months and 35% for the six months compared to the prior year. This is largely attributable to one-time sales of securities and equipment totaling approximately $505,000 recorded in the prior year's "Other Income."
- Product Revenue: Product revenues decreased due to the timing of large production scale orders for Protein A.
- Expense Reduction: Selling, general, and administrative expenses decreased significantly ($564,000 for the six months) due to reductions in administrative personnel and related expenses as part of cost reduction efforts.
- Cost of Goods Sold (COGS): COGS increased as a percentage of product sales (from 24% to 42% for the six months) primarily due to the realization of inventory previously reserved in the prior year.
- Liquidity: Cash, cash equivalents, and marketable securities decreased by 12% ($441,000) from the beginning of the fiscal year, reflecting net losses and changes in working capital components.
Outlook, Risks, and Management Commentary
Liquidity and Capital Resources: Management believes the Company has sufficient cash equivalents and marketable securities to satisfy working capital and capital expenditure requirements for the next twenty-four months. However, there can be no assurance that additional financing, if needed, will be available on favorable terms.
Unusual Items: The Company entered into a $450,000 note receivable with a licensee for past due licensing fees. As the Company historically records these fees on a cash basis, this note has not been recorded as an asset. Full payment is due in August 1998.
Risks: Future results depend on the ability to meet working capital needs, implement restructuring strategies, respond to changing technologies, and protect intellectual property rights. The Company faces competition from entities with greater financial and marketing resources.
Investor Verification Checklist
- Verify the sustainability of revenue streams given the 49% year-over-year decline and the removal of one-time asset sales from the prior year comparison.
- Confirm the collectability of the $450,000 note receivable from the licensee, which is not currently reflected on the balance sheet.
- Assess the impact of rising Cost of Goods Sold margins (42% of product sales) on future profitability.
- Monitor the burn rate of cash reserves against the stated 24-month runway projection.
- Review the status of the Company's restructuring and cost reduction initiatives to ensure continued expense discipline.